Short answer
Medtronic (MDT) filed its Q3 2026 10-Q quarterly report on Sep 3, 2026 for the quarter ended Jul 31, 2026. Quarterly revenue was $9.8B (up 13.7% year over year) with net income of $1.5B.
Q3 2026 key financials · XBRL
- Revenue
- $9.8B
- +13.7% YoY
- Net income
- $1.5B
- +41.3% YoY
- Operating margin
- 18.1%
- EPS (diluted)
- $1.14
- +40.7% YoY
Source: XBRL data from the Medtronic (MDT) Q3 2026 10-Q on SEC EDGAR. USD.
Medtronic Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $9.756B, up 14% YoY from $8.578B, including approximately $570M from the extra fiscal week
- Electrophysiology Therapies best-performing division, sales $2.218B, up 30% YoY
- Neuromodulation worst-performing division, sales $539M, up 5% YoY
- Operating cash flow $1.793B vs $1.088B YoY; free cash flow $1.290B vs $584M
- Headwinds: tariffs, pricing pressure, reimbursement challenges, currency fluctuations, supply-chain risks, and Diabetes separation costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Medtronic quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.